Publication:
Is Oral Ribavirin for the Treatment of Respiratory Syncytial Virus in High-risk Hematopoietic Stem Cell Transplant Recipients Really Safe?

Issued Date

2019-11-27

Resource Type

Letter

ISSN

15376591
10584838

DOI

10.1093/cid/ciz376

Other identifier(s)

2-s2.0-85075805521

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Clinical Infectious Diseases. Vol.69, No.12 (2019), 2234-2235

Suggested Citation

Shilpa R. Jain, Pakpoom Phoompoung, Shahid Husain Is Oral Ribavirin for the Treatment of Respiratory Syncytial Virus in High-risk Hematopoietic Stem Cell Transplant Recipients Really Safe?. Clinical Infectious Diseases. Vol.69, No.12 (2019), 2234-2235. doi:10.1093/cid/ciz376 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51299

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Is Oral Ribavirin for the Treatment of Respiratory Syncytial Virus in High-risk Hematopoietic Stem Cell Transplant Recipients Really Safe?

Author(s)

Shilpa R. Jain
 Pakpoom Phoompoung
 Shahid Husain

Other Contributor(s)

University Health Network University of Toronto
 Faculty of Medicine, Siriraj Hospital, Mahidol University

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/51299

Collections

Scopus 2019